[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578732":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":33,"locations":42,"responsibleParty":76,"collaborators":78,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":88,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":24,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":24,"overallStatus":45,"whyStopped":24,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"University of Southampton","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Kidney Stone cohort","EXPERIMENTAL","Experimental ureteric stent with specially shaped side-holes that prevent stagnation points (i.e., areas of low flow that cause particles to settle and E\\&B)",[13,14],"Device: Experimental ureteric stent with specially shaped side-holes that prevent stagnation points (i.e., areas of low flow that cause particles to settle and E&B)","Other: Qualitative interview",{"label":16,"type":10,"description":11,"interventionNames":17},"Oncology cohort",[13,14],[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DEVICE","Experimental ureteric stent with specially shaped side-holes that prevent stagnation points (i.e., areas of low flow that cause particles to settle and E&B)","Kidney stone patients and Oncology patients admitted to either the University Hospital Southampton (UHS) or University College London Hospital (UCLH) for management of kidney stones or for the management of urine drainage in ureter will have a novel ureteric stent instead of their planned conventional stent. The novel stent will be removed after 4 weeks (kidney stone patients) or 25 weeks (oncology patients). Recruitment to the cohort of oncology patients will only commence once the results for kidney stones patients have been reviewed.",[9,16],null,{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Qualitative interview","Kidney stone patients, Oncology patients and doctors will be interviewed about their experience of having a stent, or their experience in managing patients with a stent.",[9,16],[30],{"name":31,"affiliation":5,"role":32},"Ali Mosayyebi","PRINCIPAL_INVESTIGATOR",[34,38],{"name":31,"role":35,"phone":36,"phoneExt":24,"email":37},"CONTACT","02380594767","a.mosayyebi@soton.ac.uk",{"name":39,"role":35,"phone":40,"phoneExt":24,"email":41},"Sophie Varkonyi-Clifford","02381203866","cassette@soton.ac.uk",[43,62],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"University Hospital Southampton","RECRUITING","Southampton","England","SO16 6YD","United Kingdom","UK",{"type":52,"coordinates":53},"Point",[54,55],-1.40428,50.90395,{"lat":55,"lon":54},[58],{"name":59,"role":35,"phone":60,"phoneExt":24,"email":61},"Bhaskar Sohani","02381204911","bhaskar.somani@uhs.nsh.uk",{"facility":63,"status":45,"city":64,"state":64,"zip":65,"country":49,"countryCode":50,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"University College Hospital London","London","W1G 8PH",{"type":52,"coordinates":67},[68,69],-0.12574,51.50853,{"lat":69,"lon":68},[72],{"name":73,"role":35,"phone":74,"phoneExt":24,"email":75},"Daron Smith","07929716429","daron.smith1@nhs.net",{"type":77,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[79,81,84],{"name":80,"class":6},"University Hospital Southampton NHS Foundation Trust",{"name":82,"class":83},"National Institute for Health Research, United Kingdom","OTHER_GOV",{"name":85,"class":6},"University College London Hospitals","100578732","a-novel-ureteric-stent-in-kidney-stone-patients-and-oncology-patients-compared-to-a-conventional-jj-stent-100578732",false,"NCT06815120","A Novel Ureteric Stent in Kidney Stone Patients and Oncology Patients Compared to a Conventional JJ Stent","Two Single Arm, Multicentre Unblinded First-in-human Trials Investigating a Novel Ureteric Stent to Determine the Reduction of Encrustation, Biofilm Deposition and Complications Compared to a Conventional JJ Stent","CASSETTE","Inclusion Criteria:\n\n1. Aged 18 years or over\n2. Ureteric stents clinically indicated either due to kidney stones or abdominal\u002Fpelvic cancers compressing ureters\n3. Previous experience with ureteric stents\n4. Awaiting insersion\u002Freplacement of stents\n5. Ability to give consent\n6. Ability to interact with study documentation\n7. Sufficient English to complete study documentations and questionnaires\n\nExclusion Criteria:\n\n1. Expected survival \\\u003C4months\n2. Unfit for stent insertion\n3. Unable to comply with study processes Pregnancy","ALL","18 Years","99 Years",{"count":98,"type":99},50,"ESTIMATED","INTERVENTIONAL",[102],"NA","Urological stents and catheters often lead to inflammation, causing pain and infection in the urinary tract. Moreover, 80% of stents are associated with pain, negatively impacting on QoL and mental health. Offering novel designs with significantly lower E\\&B leads to a reduction in UTIs and improves QoL. Reducing hospital admissions (from 3 to 1 per patient, annually) would free \\>100,000 bed-nights, allowing the elderly to regain independence. Our proposed research could have a significant impact towards fulfilling the 'healthy-ageing' Grand Challenge. Additionally, the novel stent reduces prevalence of infections and therefore, of antibiotic prescriptions contributing to the Global AMR challenge.",[105,106,107],"Catheter Blockage","Oncology","Kidney Stone","2026-05-06",{"date":110,"type":111},"2026-05-11","ACTUAL",{"date":113,"type":111},"2025-08-06",{"date":115,"type":99},"2026-12-31",{"name":5,"class":6},2]